The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.

Stanton TamYassir Al-ZubaidiMd Khalilur RahmanKirsi BourgetFanfan ZhouMichael Murray

Published in: Pharmacological reports : PR (2022)

These findings suggest that the ixabepilone/vandetanib combination may have promise for the treatment of patients with drug-resistant TNBC.

Keyphrases